The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Advancing amyloidosis care: developments in anti-amyloid monoclonal antibodies
Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, comments on the promising developments in anti-amyloid monoclonal antibodies, noting that therapies for plasma cell disorders, such as multiple myeloma (MM), are now targeting the root cause of light chain (AL) amyloidosis, but not addressing the existing amyloid deposits in tissues. Dr Lebel highlights the potential of birtamimab and anselamimab (CAEL-101), which target and clear existing amyloid fibrils, with promising results shown in Phase III trials, particularly in advanced patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So in the field of AL amyloidosis we are fortunate to have good therapies now, but they are all coming from the world of the much more common plasma cell disorder and multiple myeloma. And all the therapies for myeloma are right now directing the plasma cell clone, which is on one hand the root of the problem that’s increased the toxic amyloidogenic light chains, but on the other hand, the light chains that are already there in the tissues, we don’t have any therapies now to clear those...
So in the field of AL amyloidosis we are fortunate to have good therapies now, but they are all coming from the world of the much more common plasma cell disorder and multiple myeloma. And all the therapies for myeloma are right now directing the plasma cell clone, which is on one hand the root of the problem that’s increased the toxic amyloidogenic light chains, but on the other hand, the light chains that are already there in the tissues, we don’t have any therapies now to clear those. And this is where birtamimab and the CAEL-101 take place as antibodies directing into those fibrils that are already deposited in the tissues and promoting their clearance. In the Phase III trial of viltamimab, it wasn’t found to be helpful in the whole population, but in the most advanced patients in stage 4, it was found to be very helpful. So now the Phase III for only these populations, which is the hardest to treat, we are all waiting for the results. The CAEL-101 is another antibody that was found to be safe and quite efficacious also in the whole AL amyloidosis populations, not only the stage 4, and we are also awaiting the study, the Phase III study results. I think in the future, if it will prove to be beneficial in first-line, maybe we should test these agents also in advanced lines in patients that were not exposed previously to these agents.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Pfizer: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees.
